CIDRAP: The scope of technologies in the Universal Influenza Vaccine Technology Landscape was expanded to include next-generation influenza vaccines, as defined in the IVR, and COVID/seasonal influenza combination vaccines in clinical development.
Milestone
3.2.a
Lessons learned from COVID-19
Completed
Identify lessons learned from COVID-19 vaccine development that are applicable to improving seasonal influenza vaccines. Include a summary of the current landscape of next-generation influenza vaccine candidates based on mRNA and other new platform technologies used in COVID-19 vaccines.
Progress Highlights
NASEM 2022 [consensus study report] provided recommendations for basic and translational research, clinical evaluation, manufacturing, and regulatory science for seasonal and pandemic influenza vaccines, based on an expert committee’s review of the rapid development, evaluation, licensing, and deployment of effective COVID-19 vaccines.
IFPMA 2022 summarized lessons learned for vaccine manufacturing during a pandemic (e.g., regarding pathogen surveillance and data sharing, equitable distribution, and pharmaceutical partnerships) to accelerate R&D and manufacturing.
Bresee 2023: WHO and LSHTM, with funding from US CDC as part of a 5-year cooperative agreement ending in 2024, are engaged in a full value of influenza vaccine assessment (FVIVA) project aimed at identifying critical success factors that would enable the development, approval, and introduction of next-generation influenza vaccines (WHO FVVA webpage). This project will also include additional lessons learned from the COVID-19 experience.